Affimed (AFMD) Competitors $0.18 -0.10 (-34.95%) As of 05/19/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock AFMD vs. BGXX, BCDA, INAB, HOTH, CSCI, DWTX, BLRX, ATHA, PHXM, and LSBShould you be buying Affimed stock or one of its competitors? The main competitors of Affimed include Bright Green (BGXX), BioCardia (BCDA), IN8bio (INAB), Hoth Therapeutics (HOTH), COSCIENS Biopharma (CSCI), Dogwood Therapeutics (DWTX), BioLineRx (BLRX), Athira Pharma (ATHA), PHAXIAM Therapeutics (PHXM), and Lakeshore Biopharma (LSB). These companies are all part of the "pharmaceutical products" industry. Affimed vs. Bright Green BioCardia IN8bio Hoth Therapeutics COSCIENS Biopharma Dogwood Therapeutics BioLineRx Athira Pharma PHAXIAM Therapeutics Lakeshore Biopharma Affimed (NASDAQ:AFMD) and Bright Green (NASDAQ:BGXX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, community ranking, earnings, profitability, institutional ownership, dividends and risk. Is AFMD or BGXX more profitable? Bright Green has a net margin of 0.00% compared to Affimed's net margin of -7,836.26%. Bright Green's return on equity of -88.37% beat Affimed's return on equity.Company Net Margins Return on Equity Return on Assets Affimed-7,836.26% -193.84% -107.24% Bright Green N/A -88.37%-55.30% Does the MarketBeat Community prefer AFMD or BGXX? Affimed received 439 more outperform votes than Bright Green when rated by MarketBeat users. CompanyUnderperformOutperformAffimedOutperform Votes43968.92% Underperform Votes19831.08% Bright GreenN/AN/A Do analysts rate AFMD or BGXX? Affimed currently has a consensus target price of $7.90, indicating a potential upside of 4,251.52%. Given Affimed's stronger consensus rating and higher probable upside, equities research analysts plainly believe Affimed is more favorable than Bright Green.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Affimed 0 Sell rating(s) 6 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.14Bright Green 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has higher earnings and valuation, AFMD or BGXX? Bright Green has lower revenue, but higher earnings than Affimed. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAffimed$877K3.33-$114.66MN/AN/ABright GreenN/AN/A-$13.13M-$0.06N/A Which has more risk and volatility, AFMD or BGXX? Affimed has a beta of 2.07, suggesting that its share price is 107% more volatile than the S&P 500. Comparatively, Bright Green has a beta of -0.26, suggesting that its share price is 126% less volatile than the S&P 500. Does the media refer more to AFMD or BGXX? In the previous week, Affimed had 16 more articles in the media than Bright Green. MarketBeat recorded 17 mentions for Affimed and 1 mentions for Bright Green. Bright Green's average media sentiment score of 0.95 beat Affimed's score of 0.01 indicating that Bright Green is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Affimed 0 Very Positive mention(s) 0 Positive mention(s) 8 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Bright Green 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders and institutionals believe in AFMD or BGXX? 30.8% of Affimed shares are owned by institutional investors. Comparatively, 7.8% of Bright Green shares are owned by institutional investors. 3.8% of Affimed shares are owned by company insiders. Comparatively, 62.5% of Bright Green shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. SummaryAffimed beats Bright Green on 8 of the 14 factors compared between the two stocks. Get Affimed News Delivered to You Automatically Sign up to receive the latest news and ratings for AFMD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AFMD vs. The Competition Export to ExcelMetricAffimedPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.92M$6.49B$5.35B$8.38BDividend YieldN/A2.66%5.22%4.10%P/E RatioN/A8.9326.5819.71Price / Sales3.33251.28391.69116.98Price / CashN/A65.8538.2534.62Price / Book0.046.466.794.50Net Income-$114.66M$143.98M$3.23B$248.18M7 Day Performance39.62%3.02%4.03%1.14%1 Month Performance-74.21%7.45%12.50%15.19%1 Year Performance-96.48%-2.42%16.73%6.55% Affimed Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AFMDAffimed4.3832 of 5 stars$0.18-34.9%$7.90+4,251.5%-96.5%$2.92M$877,000.000.00200Analyst ForecastAnalyst RevisionGap DownHigh Trading VolumeBGXXBright GreenN/AN/AN/AN/A$11.47MN/A-1.002News CoverageGap DownBCDABioCardia2.5542 of 5 stars$2.20-9.8%$25.00+1,036.4%-69.1%$11.39M$58,000.00-0.5340INABIN8bio3.1997 of 5 stars$0.13-2.9%$6.00+4,700.0%-87.5%$11.35MN/A-0.1720HOTHHoth Therapeutics3.2892 of 5 stars$0.85-1.2%$4.00+370.6%-29.5%$11.23MN/A-0.644CSCICOSCIENS BiopharmaN/A$3.48+4.2%N/AN/A$10.95M$9.59M-0.2920Gap DownDWTXDogwood Therapeutics1.1928 of 5 stars$5.71+7.3%$10.00+75.1%N/A$10.91MN/A-0.875BLRXBioLineRx1.6396 of 5 stars$3.27+0.9%$26.00+695.1%-85.4%$10.89M$28.94M-0.3740Upcoming EarningsATHAAthira Pharma1.6902 of 5 stars$0.27flat$13.83+4,985.8%-89.4%$10.62MN/A-0.1040PHXMPHAXIAM TherapeuticsN/A$3.10flatN/AN/A$10.58M$32.66M0.0049LSBLakeshore Biopharma0.6974 of 5 stars$1.13+5.6%N/AN/A$10.52M$672.27M0.00773 Related Companies and Tools Related Companies BGXX Competitors BCDA Competitors INAB Competitors HOTH Competitors CSCI Competitors DWTX Competitors BLRX Competitors ATHA Competitors PHXM Competitors LSB Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AFMD) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredThe Prophet's Newest PredictionA storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when pu...Stansberry Research | SponsoredA new financial chapter Porter Stansberry says what happened last week could become the defining legacy of his financial publishing ca...Porter & Company | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon’s backup plan for AIElon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredExclusive Offer: Target 100% Returns NowBrace yourself–this may come as a shock. It turns out that you may not have to wait decades to turn a small...ProsperityPub | Sponsored🚨 Nvidia Just Inked a $7B AI Deal—This Could Change EverythingOn Wednesday, Nvidia stock surged—again. Why? Because Saudi Arabia just announced a multi-billion-dollar AI...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Affimed Please log in to your account or sign up in order to add this asset to your watchlist. Share Affimed With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy AFMD Stock Free AFMD Stock Alerts